Shanghai Henlius Biotech, Inc.

SEHK:2696 Stock Report

Market Cap: HK$13.0b

Shanghai Henlius Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

SEHK:2696 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Sep 24SellHK$4,837,459Loyal Valley CapitalCompany209,848HK$23.05
08 Jul 24BuyHK$25,396,040Loyal Valley CapitalCompany1,112,500HK$22.83
09 May 24SellHK$1,391,268Qatar Holding LLCCompany80,700HK$17.24

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 2696?
Owner TypeNumber of SharesOwnership Percentage
Public Companies00%
Individual Insiders3,181,6500.585%
Institutions40,518,5607.46%
General Public116,299,05221.4%
Private Companies383,495,59170.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 21 shareholders own 78.6% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
48.9%
Shanghai Fosun New Medicine Research Company Limited
265,971,569HK$6.3b0%no data
8.05%
Henlius Biopharmaceuticals, Inc.
43,756,960HK$1.0b0%no data
5.95%
Fosun Industrial Co., Limited
32,331,100HK$771.1m0%no data
4.67%
Shanghai Fosun Pharmaceutical Development Co., Ltd.
25,393,818HK$605.6m0%no data
2.99%
UBS Asset Management AG
16,262,303HK$387.9m60.8%no data
2.92%
Henlink, Inc.
15,876,694HK$378.7m0%no data
2.09%
Qatar Holding LLC
11,370,960HK$271.2m0%0.08%
1.5%
Loyal Valley Capital
8,155,084HK$194.5m0%3.55%
0.44%
Shi-Kau Liu
2,410,695HK$57.5m0%no data
0.31%
Morgan Stanley, Investment Banking and Brokerage Investments
1,705,420HK$40.7m0%no data
0.31%
Dubai International Capital L.L.C.
1,684,899HK$40.2m0%2.33%
0.13%
Wei-Dong Jiang
720,955HK$17.2m0%no data
0.11%
Pictet Asset Management Limited
613,300HK$14.6m0%no data
0.052%
Pictet Asset Management (Singapore) Pte Ltd
284,400HK$6.8m0%1.11%
0.034%
Dimensional Fund Advisors LP
185,623HK$4.4m0%no data
0.03%
Shanghai Guoyun Biotech Partnership Enterprise (Limited Partnership)
165,450HK$3.9m0%no data
0.028%
State Street Global Advisors, Inc.
150,900HK$3.6m-1.31%no data
0.017%
ICBC Credit Suisse Asset Management Co., Ltd.
90,000HK$2.1m0%no data
0.0092%
Jun Zhu
50,000HK$1.2m0%no data
0.0028%
Fundmarket A/S
15,000HK$357.8k0%0.06%
0.00012%
BMO Asset Management Corp.
671HK$15.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 04:24
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Henlius Biotech, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Wangbin ZhouCitigroup Inc
Eva ZhaoCitigroup Inc